Kovitz Investment Group Partners LLC Sells 16,658 Shares of Sanofi (NASDAQ:SNY)

Kovitz Investment Group Partners LLC lowered its stake in Sanofi (NASDAQ:SNY) by 21.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 60,544 shares of the company’s stock after selling 16,658 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Sanofi were worth $3,356,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GFS Advisors LLC raised its position in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares in the last quarter. Legacy Capital Wealth Partners LLC increased its stake in shares of Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock valued at $1,399,000 after purchasing an additional 12,942 shares during the last quarter. Icon Wealth Advisors LLC raised its holdings in shares of Sanofi by 7,954.4% during the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after buying an additional 289,144 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Sanofi by 15.2% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock worth $5,673,000 after buying an additional 15,439 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Sanofi in the third quarter valued at about $8,728,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on SNY. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Down 0.1 %

Shares of SNY stock opened at $48.46 on Monday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $122.98 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.23 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock’s fifty day simple moving average is $51.90 and its 200 day simple moving average is $52.11.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the firm posted $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, sell-side analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.